Research programme: diabetes/obesity therapy - Serono Genetics Institute

Drug Profile

Research programme: diabetes/obesity therapy - Serono Genetics Institute

Alternative Names: Famoxin; gAPM1

Latest Information Update: 28 Nov 2007

Price : $50

At a glance

  • Originator INSERM; Serono Genetics Institute
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 25 Oct 2002 Genset has been acquired by Serono
  • 20 May 2002 Genset has selected Eurogentec to manufacture Famoxin
  • 08 Aug 2001 Genset has announced the production of the human protein fragment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top